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The use of acoustic radiation force-based shear stiffness
in non-alcoholic fatty liver disease
beneﬁt of a non-invasive test. It would be useful to assess the
diagnostic accuracy of the test between different stages of ﬁbrosis
from F0 vs. F1–4 to F0123 vs. F4. One could then derive meaning-
ful cut-offs to help guide clinical decisions based on the sensitiv-
ity, speciﬁcity, negative and positive predictive values as well as
positive and negative likelihood ratios, of a respective test.
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JOURNAL OF HEPATOLOGYTo the Editor:
Palmeri and colleagues are to be congratulated on their study
assessing the utility of acoustic radiation force image impulse
(ARFI) to assess the severity of liver ﬁbrosis in patients with
non-alcoholic fatty liver disease (NAFLD) [1]. However, there
are several aspects from the study that need to be addressed.
Firstly, the number of unsuccessful stiffness reconstructions is
signiﬁcant at 37/172 (21.5%). This would represent a major draw-
back for any screening test used to gauge the severity of underly-
ing liver ﬁbrosis. In addition, the area under the curve (AUC) of
0.9 for the threshold given (P4.24 kPa) should be re-calculated
considering the frequency of the ﬁbrosis stages and the distribu-
tion of non-advanced and advanced liver ﬁbrosis (DANA) in the
study population using the method described by Poynard and
colleagues [2]. In common with all studies evaluating the accu-
racy of non-invasive markers using liver biopsy as the gold stan-
dard, the authors have omitted failed examinations from the ﬁnal
analysis. This is misleading as the accuracy and reproducibility of
ARFI is then conﬁned to successful readings and not the study
population as a whole. I think all such studies should have a sta-
tistical test similar to ‘‘an intention-to-treat’’ analysis in clinical
drug trials so that the accuracy of the study test is applied in
the context of an entire study population and not only those in
whom a result is achieved. Furthermore, as can be seen from
Fig. 2, the shear modulus across the liver ﬁbrosis stages is very
narrow from stage 0 to stage 4. Once again, this may make
interpretation of results difﬁcult, particularly for the lesser stages
i.e. stages F0–2, when clinicians may wish to identify early
disease to act early to prevent disease progression. This group
of patients is still likely to require a liver biopsy to differentiate
non-alcoholic steatohepatitis from NAFLD, negating the primeJournal of Hepatology 2012 vol. 56 j 993–999 995
